T1	Premise 809 921	There was significant early attrition due to disease progression; only 61.5% of patients were alive at 2 months.
T2	Premise 922 1093	There was a significant improvement in KP from baseline to pre-cycle 3 in both arms, with a trend in favor of the 3w4 regimen for duration and faster onset of improvement.
T3	Premise 1094 1253	Eight of the 17 quality-of-life (QOL) variables assessed showed an improvement of more than 10% between baseline and the start of the third cycle of treatment.
T4	Premise 1254 1318	Response rate, survival, and duration were similar in both arms.
T5	Claim 1319 1488	There was no significant difference between the two schedules examined in terms of improvement in KP or QOL, but there seemed to be a trend in favor of the 3w4 schedule.
R2	Support Arg1:T4 Arg2:T5	
R3	Support Arg1:T3 Arg2:T5	
R4	Support Arg1:T2 Arg2:T5	
R5	Partial-Attack Arg1:T1 Arg2:T5	
